Current Report Filing (8-k)
April 03 2018 - 7:10AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported): April 3, 2018
TONIX
PHARMACEUTICALS HOLDING CORP.
(Exact
name of registrant as specified in its charter)
Nevada
|
001-36019
|
26-1434750
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
509
Madison Avenue, Suite 306, New York, New York 10022
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
(212) 980-9155
Copy
of correspondence to:
Michael
J. Lerner, Esq.
Lowenstein
Sandler LLP
One
Lowenstein Drive
Roseland,
NJ 07068
Tel:
(973) 597-2500 Fax: (973) 597-6395
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01
|
Regulation
FD Disclosure.
|
Tonix
Pharmaceuticals Holding Corp. (the “Company”) updated its investor presentations, which are used to conduct meetings
with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website,
which may contain nonpublic information. Copies of the presentations are filed as Exhibit 99.01, 99.02 and 99.03 hereto and incorporated
herein by reference.
On
April 3, 2018, the Company issued a press release announcing that 50% of the planned total number of participants in the Phase
3 HONOR study evaluating Tonmya®, or TNX-102 SL 5.6 mg, for the bedtime treatment of military-related posttraumatic stress
disorder, have been randomized. A copy of the press release is filed as Exhibit 99.04 hereto and incorporated herein by reference.
The
information in this Current Report, including all exhibits, is being furnished and shall not be deemed “filed” for
the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The
information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant
to the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing, and is not deemed
an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation
FD.
Item
9.01
|
Financial
Statements and Exhibits.
|
(d) Exhibits.
*
Furnished herewith.
SIGNATURE
Pursuant
to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
TONIX PHARMACEUTICALS HOLDING
CORP.
|
|
|
|
Date: April
3, 2018
|
By:
|
/s/
Bradley Saenger
|
|
|
Bradley Saenger
|
|
Chief Financial Officer
|
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2023 to Apr 2024